Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Separately, FBR & Co reissued an “outperform” rating and issued a $3.00 price target on shares of Rexahn Pharmaceuticals in a research note on Wednesday, October 5th.
Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.1817 on Wednesday. The firm’s market cap is $38.76 million. The firm’s 50 day moving average price is $0.23 and its 200 day moving average price is $0.27. Rexahn Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $0.52.
Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. Equities research analysts anticipate that Rexahn Pharmaceuticals will post ($0.07) EPS for the current fiscal year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.